Alto Neuroscience (ANRO) Cash & Equivalents (2023 - 2026)

Alto Neuroscience has reported Cash & Equivalents for 4 years, with the latest figure at $263.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 64.08% year-over-year to $263.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263.8 million (up 64.08% YoY) and the FY2025 annual result came in at $176.5 million, up 4.93% from the prior year.
• Cash & Equivalents rose to $263.8 million in Q1 2026 per ANRO's latest filing, from $176.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $263.8 million in Q1 2026 and troughed at $82.5 million in Q4 2023.
• A 4-year average of $171.8 million and a median of $172.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 103.76% in 2024, then decreased 24.15% in 2025.
• Over 4 years, Cash & Equivalents stood at $82.5 million in 2023, then jumped by 103.76% to $168.2 million in 2024, then climbed by 4.93% to $176.5 million in 2025, then soared by 49.45% to $263.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $263.8 million, $176.5 million, and $137.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.